Health Care Equipment

Globus Medical Inc 

Stifel Nicolaus Analyst Thomas Stephan Reiterates Globus Medical Hold Rating

Globus Medical Inc. released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 759.85 M (forecast USD 740.83 M), actual EPS USD 0.9 (forecast USD 0.755)

Globus Medical Q1 Earnings Exceed Expectations

Globus Medical Inc. to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 740.83 M, EPS USD 0.755

Globus Medical Raises 2026 Fiscal Year Guidance

BofA Securities Reiterates Buy Rating on Globus Medical

Globus Medical Inc. released FY2025 Q4 earnings on February 24 After-Market EST, actual revenue USD 826.42 M (forecast USD 803.29 M), actual EPS USD 1.0201 (forecast USD 0.9625)

Globus Medical Inc. released FY2025 earnings on February 24 After-Market EST, actual revenue USD 2.939 B (forecast USD 2.913 B), actual EPS USD 3.92 (forecast USD 3.9562)

Globus Medical Inc. to release FY2025 Q4 earnings on February 24 After-Market EST, forecast revenue USD 803.29 M, EPS USD 0.9625

Ryan Zimmerman Reiterates Hold Rating on Globus Medical

TD Cowen initiates a Buy rating on Globus Medical with a target price of $110

Globus Medical's CFO Sells Company Shares

Globus Medical's Premarket Stock Price Rises to New High

Globus Medical Inc. Sets 2026 Revenue Guidance at $3.18B to $3.22B

Globus Medical Director Norwalk Reports Sale of Class A Common Stock

Braidwell LP Increased Holdings of Globus Medical in Q2

FactSet Raises Target Price Estimate for Globus Medical

Globus Medical Inc CFO Kline Kyle sold 18,542 shares

Globus Medical Receives Broker Ratings and Internal Directors' and Executives' Stock Sales

Globus Medical's Senior VP Kelly Huller Disposes of Company Shares

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

GMED

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in Globus Medical, Inc. (NYSE:GMED) by 58% in Q4, selling 17,300 shares. The firm now holds 12,510 shares valued at $1,092,000. Other institutional investors have also adjusted their stakes, with AQR Capital Management increasing its holdings by 45.9%. Analysts have set price targets for GMED, with an average target of $106.36. The stock opened at $76.52, with a market cap of $10.39 billion and a recent earnings report showing a 27% revenue increase year-over-year.

Market Beat

Truist Financial

ROYAL BANK OF CANADA

Wells Fargo

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

VIRGINIA RETIREMENT SYSTEMS ET Al Sells 17,300 Shares of Globus Medical, Inc. $GMED

CFRA maintains a Hold opinion on Globus Medical Inc. (GMED) shares, lowering the target price to $84 from $98. They raised the 2026 EPS estimate to $4.72 and 2027 EPS to $4.98. GMED reported a strong Q1 2026 with a 27% revenue increase to $759.9M and a 64.7% rise in adjusted EPS to $1.12. Growth was driven by the U.S. Spine business, but revenue from the Nevro business declined due to restructuring, indicating potential execution risks ahead.

Fidelity

iShares US Medical Devices

SPDR S&P Health Equip

Nevro

Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.

Stifel Nicolaus analyst Thomas Stephan has reaffirmed a Hold rating on Globus Medical (GMED) with a price target of $95.00, while the shares closed at $77.95. The analyst has a 5.1% average return and a 40.91% success rate. The overall analyst consensus for Globus Medical is a Strong Buy, with an average price target of $110.90.

Tip Ranks

Stifel Financial

TransMedics

Alphatec

Bausch + Lomb

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Reaffirms Their Hold Rating on Globus Medical (GMED)

Wall Street Zen downgraded Globus Medical (NYSE:GMED) from a "strong-buy" to a "buy" rating. Other analysts have mixed views, with Royal Bank of Canada raising its price target to $120 and Needham to $117, both maintaining positive ratings. The stock opened at $77.81, with a market cap of $10.52 billion. Globus Medical reported strong Q1 earnings, beating estimates with $1.12 EPS and $759.85 million in revenue, a 27% increase year-over-year. The company also raised its FY 2026 EPS guidance to $4.70-$4.80, indicating growth confidence.

Bank of Montreal

Invesco

AllianceBernstein

Globus Medical (NYSE:GMED) Stock Rating Lowered by Wall Street Zen

Royal Bank Of Canada raised its price target for Globus Medical (NYSE:GMED) from $115.00 to $120.00, maintaining an "outperform" rating. This new target suggests a potential upside of 51.72% from the previous close. Other analysts have also increased their price targets, with Canaccord Genuity setting it at $112.00 and Needham at $117.00. The stock traded down to $79.09, with a market cap of $10.70 billion. Globus Medical reported strong quarterly earnings, exceeding estimates with a revenue of $759.85 million, up 27% year-over-year.

Canadian Imperial Bank Comm

Bank7

Blaize

Zenas Biopharma

Zimmer Biomet

Nano Labs

Genuit Group PLC

Carlyle

Capital Group New Geography Equity ETF

CF Industries

Landbridge Co LLC

New England Real Asso

Newton Golf Company

Barclays

Piper Sandler Cos

Toronto Dominion Bank

GS MarketBeta US Equity ETF

MarketWise

Value Line

SBI Holdings, Inc.

SBI Insurance Group Co., Ltd.

San Holdings, Inc. (Japan)

Advantage Solutions

PMV Adaptive Risk Parity ETF

Network 1 Tech

Eversource Energy

Everquote

WealthNavi, Inc.

Lakeland Financial

Clarkson PLC

Donnelley Financial Solution

First Horizon

BLAIZE HOLDINGS INC C/WTS 13/01/2030 (TO PUR COM)

ADVANTAGE SOLUTIONS INC C/WTS 28/10/2025(TO PUR COM)

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Globus Medical (NYSE:GMED) Given New $120.00 Price Target at Royal Bank Of Canada

Globus Medical (GMED) saw its stock drop over 8% to $78.04 despite reporting better-than-expected first-quarter results. The company had initially gained 7% in aftermarket trading on Thursday but lost momentum on Friday, erasing those gains.

Globus Medical tanks 8% despite beating estimates for top and bottom lines

Wells Fargo analyst Larry Biegelsen has reaffirmed a Buy rating on Globus Medical (GMED) with a price target of $103. The analyst consensus for GMED is a Strong Buy, with an average price target of $112.10. Biegelsen has a 46.71% success rate on his stock recommendations in the Healthcare sector, which includes companies like Abbott Laboratories and Medtronic.

Abbott Laboratories

Medtronic

DexCom

Wells Fargo Reaffirms Their Buy Rating on Globus Medical (GMED)

Needham analyst David Saxon has reaffirmed a Buy rating on Globus Medical (GMED) with a price target of $117.00. The analyst consensus for Globus Medical is a Strong Buy, with an average price target of $112.20. Saxon focuses on the Healthcare sector and has an average return of -2.3% with a 31.63% success rate on his stock recommendations.

Dentsply Sirona

Sight Sciences

RxSight

Needham Reaffirms Their Buy Rating on Globus Medical (GMED)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

Globus Medical (GMED) Q1 2026 Earnings Transcript

CTKB

In Thursday's after-market session, several health care stocks experienced significant movements. Maravai LifeSciences (MRVI) rose 18.5% to $4.67, while Progyny (PGNY) increased by 14.56% to $21.95. Tandem Diabetes Care (TNDM) saw a 12.12% rise to $20.71. Conversely, Artivion (AORT) fell 20.9% to $28.0, and Arcturus Therapeutics (ARCT) declined by 19.11% to $7.2. Other notable gainers included Accuray (ARAY) and Globus Medical (GMED), while losers included Cytek Biosciences (CTKB) and Caris Life Sciences (CAI). All companies reported Q1 earnings today.

Globus Medical Inc (GMED.US)